(Q35945466)

11 August 2017

1 reference

title

Drug-eluting stents: a mechanical and pharmacologic approach to coronary artery disease (English)

1 reference

11 August 2017

main subject

coronary artery disease

1 reference

Paul P Dobesh

1

1 reference

11 August 2017

Zachary A Stacy

series ordinal

2

1 reference

11 August 2017

Alexander J Ansara

series ordinal

3

1 reference

11 August 2017

Jason M Enders

series ordinal

4

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 November 2004

1 reference

11 August 2017

1 reference

11 August 2017

volume

24

1 reference

11 August 2017

issue

11

1 reference

11 August 2017

page(s)

1554-1577

1 reference

Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Restenosis after coronary angioplasty: a multivariate statistical model to relate lesion and procedure variables to restenosis. The M-HEART Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Improved clinical outcome after widespread use of coronary-artery stenting in Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Randomized comparison of coronary stent implantation and balloon angioplasty in the treatment of de novo coronary artery lesions (START): a four-year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Meta-analysis of the effect of diabetes on restenosis rates among patients receiving coronary angioplasty stenting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Local delivery of enoxaparin to decrease restenosis after stenting: results of initial multicenter trial: Polish-American Local Lovenox NIR Assessment study (The POLONIA study)

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Coronary restenosis: a review of mechanisms and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Intravascular ultrasound insights into mechanisms of stenosis formation and restenosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Neointimal tissue response at sites of coronary stenting in humans: macroscopic, histological, and immunohistochemical analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Mechanisms of angioplasty and stent restenosis: implications for design of rational therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Binding to heparan sulfate or heparin enhances neutrophil responses to interleukin 8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Enhanced extracellular matrix accumulation in restenosis of coronary arteries after stent deployment

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Production of transforming growth factor beta 1 during repair of arterial injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Induction of angiotensin converting enzyme in the neointima after vascular injury. Possible role in restenosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Human protein disulfide isomerase functionally complements a dsbA mutation and enhances the yield of pectate lyase C in Escherichia coli.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

New frontiers in cardiology: drug-eluting stents: Part I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Bench to bedside: the development of rapamycin and its application to stent restenosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Rapamycin inhibits vascular smooth muscle cell migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Sirolimus-eluting coronary stents

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Oral everolimus inhibits in-stent neointimal growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Study of antirestenosis with the BiodivYsio dexamethasone‐eluting stent (STRIDE): A first‐in‐human multicenter pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Pharmacologic roles of heparin and glucocorticoids to prevent restenosis after coronary angioplasty.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Estrogen-eluting, phosphorylcholine-coated stent implantation is associated with reduced neointimal formation but no delay in vascular repair in a porcine coronary model

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Estrogen regulation of endothelial and smooth muscle cell migration and proliferation: role of p38 and p42/44 mitogen-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Drug-eluting stents in vascular intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Drug-eluting stents in preclinical studies: recommended evaluation from a consensus group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Coated stents for the prevention of restenosis: Part II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Coated stents for the prevention of restenosis: Part I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Novel drug-delivery stent: intravascular ultrasound observations from the first human experience with the QP2-eluting polymer stent system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Pathological analysis of local delivery of paclitaxel via a polymer-coated stent

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Stent-based antirestenotic coatings (sirolimus/paclitaxel).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Intravascular ultrasound assessment of patterns of arterial remodeling in the absence of significant reference segment plaque burden in patients with coronary artery disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary Artery

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Sirolimus-eluting stent for treatment of complex in-stent restenosis: the first clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Sirolimus-eluting stent for the treatment of in-stent restenosis: a quantitative coronary angiography and three-dimensional intravascular ultrasound study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

A paclitaxel-eluting stent for the prevention of coronary restenosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Coronary restenosis elimination with a sirolimus eluting stent: first European human experience with 6-month angiographic and intravascular ultrasonic follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation: long-term (up to 2 years) clinical, angiographic, and intravascular ultrasound follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Small stent size and intimal hyperplasia contribute to restenosis: A volumetric intravascular ultrasound analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Angiographic findings of the multicenter Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL): sirolimus-eluting stents inhibit restenosis irrespective of the vessel size

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Fate of side branches after coronary arterial sirolimus-eluting stent implantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

A long-term perspective on the protective effects of an early invasive strategy in unstable coronary artery disease: two-year follow-up of the FRISC-II invasive study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Early outcome after sirolimus-eluting stent implantation in patients with acute coronary syndromes: insights from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Sirolimus-eluting stent implantation in ST-elevation acute myocardial infarction: a clinical and angiographic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Paclitaxel coating reduces in-stent intimal hyperplasia in human coronary arteries: a serial volumetric intravascular ultrasound analysis from the Asian Paclitaxel-Eluting Stent Clinical Trial (ASPECT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Coronary in-stent restenosis: current status and future strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

ACC/AHA Guideline Update for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction--2002: Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice G

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Drug-eluting stents and glycoprotein IIb/IIIa inhibitors: Combination therapy for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.24.16.1554.50955

10.1592/PHCO.24.16.1554.50955

21 January 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference